Fig. 1

TDRKH-AS1 is overexpressed in BC tissues and cell lines. A, B The TCGA and starBase database results showed that TDRKH-AS1 expression was obviously upregulated in BC tissues compared with normal tissues. ^∗∗∗P < 0.001 vs. Normal group. C The UALCAN database results showed that TDRKH-AS1 expression was obviously upregulated in in different BC molecular subtypes including luminal, HER2-positive and TNBC compared with normal tissues. ^∗∗∗P < 0.001 vs. Normal group. D, E The GEO database displayed that TDRKH-AS1 expression was upregulated in BC tissues. ^∗∗P < 0.01 vs. Paracancerous group. F The OS curves of BC patients were generated by Kaplan–Meier analysis from TCGA database. Elevated TDRKH-AS1 expression was associated with a poor prognosis in patients. G GEPIA database was used to analyze the impact of TDRKH-AS1 expression levels on clinical prognosis, including OS and RFS. H The ROC curves analysis showed that TDRKH-AS1 could be a latent discriminator between breast cancer and normal tissues. I Expression levels of TDRKH-AS1 in BC cell lines were detected by RT-qPCR. ^∗P < 0.05 ^∗∗P < 0.01 vs. control group. J, K RT-qPCR detected expression levels of TDRKH-AS1 in clinical samples. ^∗P < 0.05 vs. Normal group